Immunothérapie tumorale

Cancer treatment vaccines are designed using dendritic cells loaded with tumor antigens from the patient's own cancer cells. These antigen-presenting cells stimulate an immune response, training the body to recognize and attack cancer cells. This approach leverages the patient's adaptive immune system to target malignant cells specifically.

Adoptive cell therapy modifies a patient's T cells to express chimeric antigen receptors, or CARs, which enable direct recognition of cancer cells. Once reinfused into the patient, CAR T cells bind to specific tumor antigens and destroy cancer cells. This personalized approach harnesses the patient's own immune cells as targeted cancer fighters.

Oncolytic virus therapy uses genetically modified viruses, such as T-VEC, a herpes virus variant, to selectively infect and lyse cancer cells. When tumor cells rupture, they release tumor antigens that trigger additional cytotoxic T cell responses. This dual mechanism combines direct cell destruction with immune system activation.

Tumor cells exploit immune checkpoint proteins like CTLA-4 on T cells to suppress immune responses. Checkpoint inhibitor antibodies, such as ipilimumab, block these interactions, preventing tumor cells from evading immunity. By removing this inhibition, these antibodies enhance T cell proliferation and activation against tumor antigens.

Cancer cells evade immunity through rapid mutation and division, allowing them to avoid recognition by immune surveillance mechanisms. The immune response to cancer involves three phases: elimination, equilibrium, and escape. Understanding these phases helps researchers develop strategies to enhance early immune responses and prevent tumor escape.

Immunotherapy can be delivered through multiple routes including intravenous, oral, topical, and intravesical administration. Treatment frequency and duration depend on cancer type, stage, the specific immunotherapy used, and the patient's response. Regular medical check-ups and tests monitor treatment effectiveness and guide adjustments.

Cancer immunotherapy includes several strategies: immune checkpoint inhibitors, T-cell transfer therapy, monoclonal antibodies, treatment vaccines, and immune system modulators. Each approach targets different mechanisms to enhance the body's ability to recognize and eliminate cancer cells. These therapies work by boosting or manipulating immune responses against malignant tumors.